Aberrations of an IR chopping secondary: authors’ reply to comment 2 and continuation of authors’ reply to comment 1Meinel, Aden B.; Meinel, Marjorie P. · ao/24/7/ao-24-7-944.pdf · 1985

Authors' ReplyNysom, Karsten; Hesse, Birger · Medical and Pediatric Oncology · 1998

AUTHORS’ REPLYAMBRASEYS, N. N.; SIMPSON, K. A.; BOMMER, J. J. · Earthquake Engineering & Structural Dynamics · 1997

AUTHORS' REPLY.WANG, DA-GONG; JOHNSTON, COLIN F. · The Journal of Pathology · 1996

AUTHORS' REPLY.TAMURA, G.; MAESAWA, C.; SATODATE, R. · The Journal of Pathology · 1996

AUTHORS' REPLYMcQUAID, S.; McCONNELL, R.; McMAHON, J.; HERRON, B. · The Journal of Pathology · 1996

AUTHORS' REPLYMcMANUS, AIDAN P.; GUSTERSON, BARRY A.; PINKERTON, C. ROSS; SHIPLEY, JANET M. · The Journal of Pathology · 1996

Authors' ReplySeko, Yoshinori; Yazaki, Yoshio · The Journal of Pathology · 1997

Infliximab Treatment of SarcoidosisSerio, Ryan N · The Annals of Pharmacotherapy · 2003

Community Pharmacy Services in PortugalCosta, S.; Santos, C.; Silveira, J. · Annals of Pharmacotherapy · 2006

Bioavailability of DigoxinFrancke, D. E · Annals of Pharmacotherapy · 2006

Nelfinavir mesylate: a protease inhibitorPai, V. · Annals of Pharmacotherapy · 1999

Pharmacoeconomics: Historical PerspectiveBootman, J L. · Annals of Pharmacotherapy · 2006

Handbook of Anticancer Pharmacokinetics and PharmacodynamicsGwilt, P. R · Annals of Pharmacotherapy · 2004

Mifepristone: Less Obvious Adverse EffectsRudd, Gene · The Annals of Pharmacotherapy · 2001

Pharmaceutical Care, 2nd EditionJones, Mark · The Annals of Pharmacotherapy · 2003